Nuvectis Pharma Net Income

The latest net income for NVCT is $-30M as of June 2026. That compares with $-22M in the prior-year period — down 37.2% year over year. That is below the sector sector average of $96M. Investors often review this figure alongside Nuvectis Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVCT's net income moved from $-22M to $-30M — a 37.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nuvectis Pharma's operating scale or balance-sheet position.

Against its sector companies, NVCT currently prints $-30M for net income, while the sector average sits near $96M. That is roughly 131.4% below the sector mean. Large gaps often invite a closer look at Nuvectis Pharma's growth, margins, and balance sheet.

A net income figure of $-30M for NVCT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $96M. Explore the charts below for those layers of context.

After noting NVCT's net income ($-30M), review year-over-year change from $-22M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.